We are focused on developing innovative technology that could continuously contribute to medical diagnosis even in the circumstances of rapidly changing IVD market.
Our development goal is to realize prompt and accurate MDx even when there are low quantity of pathogens from various diseases.
Realize prompt and accurate molecular diagnostics and support early-stage
diagnosis and timely personalized medicine.
We are developing nucleic acid preparation and MDx and CDx technology targeting various infectious diseases and genetic disorders including COVID-19, mycobacterium tuberculosis,
fungal diseases, Orientia tsutsugamushi and liquid biopsy from cancers.